{"preliminary_commentary":{"by_channel":{"x_thread":10,"podcast":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06151574\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["zongertinib"]],"indication":null,"name":"Beamion LUNG-2","nct_id":"NCT06151574","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=beamion-lung-2-nct06151574. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"zongertinib only","label":"Experimental treatment arm","type":"EXPERIMENTAL"},{"description":"pembrolizumab plus platinum-pemetrexed chemotherapy","label":"Comparator arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-01-28","type":"ESTIMATED"},"conditions":["Lung Cancer, Non-squamous, Non-small Cell"],"enrollment":{"count":428,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"zongertinib","otherNames":["BI 1810631, Hernexeos®"],"type":"DRUG"},{"name":"pembrolizumab","otherNames":["Keytruda®"],"type":"DRUG"},{"name":"cisplatin","otherNames":[],"type":"DRUG"},{"name":"carboplatin","otherNames":[],"type":"DRUG"},{"name":"pemetrexed","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-01","lead_sponsor":"Boehringer Ingelheim","official_title":"Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 determined by blinded central independent review","timeFrame":"up to 4 years and 5 months"}],"references":[{"citation":"Puri S, Ismaila N, Azar IH, Freeman-Daily J, Furuya N, Kuruvilla S, Roof L, Velazquez AI, Wang Y, Wheatley Price P, Leighl NB. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2. J Clin Oncol. 2026 Sep 10;44(26):e127-e139. doi: 10.1200/JCO-26-01479. Epub 2026 Jun 29.","pmid":"42372216","type":"DERIVED"}],"start_date":{"date":"2024-02-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","url":"https://clinicaltrials.gov/study/NCT06151574"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/beamion-lung-2-nct06151574"}